Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An instance of hyperparathyroidism that is caused by an inherited genomic modification in an individual.
Biomarker and diagnostic research for hereditary hyperparathyroidism has been reported in the published literature.
No clinical trials have been registered for hereditary hyperparathyroidism.
101 publications have been identified in PubMed for hereditary hyperparathyroidism. Research spans Review / Meta-Analysis (62%), Basic Science / Preclinical (14%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 53 | 62% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 1:02 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research
12 |
14% |
Disease patterns and progression | 9 | 10% |
Patient case studies | 7 | 8% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
New treatment approaches | 1 | 1% |
Charoenngam N (2026). [PMID: 41685558](https://pubmed.ncbi.nlm.nih.gov/41685558/). *Endocr Relat Cancer*. [Review / Meta-Analysis]
Halperin R (2026). [PMID: 42009220](https://pubmed.ncbi.nlm.nih.gov/42009220/). *Endocr Pract*. [Epidemiology / Natural History]
Naveh-Many T (2026). [PMID: 42199077](https://pubmed.ncbi.nlm.nih.gov/42199077/). *Curr Opin Nephrol Hypertens*. [Review / Meta-Analysis]
Helbing A (2026). [PMID: 30085580](https://pubmed.ncbi.nlm.nih.gov/30085580/). *Unknown Journal*. [Case Report / Case Series]
Htoo STY (2025). [PMID: 40683368](https://pubmed.ncbi.nlm.nih.gov/40683368/). *Endocr Pract*. [Review / Meta-Analysis]
Ladsous M (2025). [PMID: 39818302](https://pubmed.ncbi.nlm.nih.gov/39818302/). *Ann Endocrinol (Paris)*. [Review / Meta-Analysis]
Marini F (2025). [PMID: 39939267](https://pubmed.ncbi.nlm.nih.gov/39939267/). *Best Pract Res Clin Endocrinol Metab*. [Review / Meta-Analysis]
Gu Y (2025). [PMID: 40383453](https://pubmed.ncbi.nlm.nih.gov/40383453/). *Ann Endocrinol (Paris)*. [Diagnostic / Biomarker]
Al-Salameh A (2025). [PMID: 39818298](https://pubmed.ncbi.nlm.nih.gov/39818298/). *Ann Endocrinol (Paris)*. [Review / Meta-Analysis]
Simonds WF (2025). [PMID: 39775826](https://pubmed.ncbi.nlm.nih.gov/39775826/). *J Clin Endocrinol Metab*. [Review / Meta-Analysis]